2020
DOI: 10.1021/acs.jmedchem.0c00531
|View full text |Cite
|
Sign up to set email alerts
|

Design, Synthesis, and Pharmacological Evaluation of Analogues Derived from the PLEV Tetrapeptide as Protein–Protein Interaction Modulators of Voltage-Gated Sodium Channel 1.6

Abstract: The voltage-gated Na+ (Nav) channel is the molecular determinant of excitability. Disruption of protein–protein interactions (PPIs) between Nav1.6 and fibroblast growth factor 14 (FGF14) leads to impaired excitability of neurons in clinically relevant brain areas associated with channelopathies. Here, we designed, synthesized, and pharmacologically characterized new peptidomimetics based on a PLEV tetrapeptide scaffold derived from the FGF14:Nav1.6 PPI interface. Addition of an N-terminal 1-adamantanecarbonyl … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
13
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 8 publications
(17 citation statements)
references
References 57 publications
4
13
0
Order By: Relevance
“…To evaluate the hypothesis that PLEV and/or EYYV could modulate FGF14:Nav1.6 complex assembly, an in-cell assay was used with a HEK293 cell line (hereafter coded as "Clone V" cells) stably expressing both CLuc-FGF14 and CD4-Nav1.6-NLuc (Shavkunov et al, 2012;Shavkunov et al, 2013;Shavkunov et al, 2015;Ali et al, 2016Ali et al, , 2018Wadsworth et al, 2019Wadsworth et al, , 2020Dvorak et al, 2020Dvorak et al, , 2021Singh et al, 2020;Wang et al, 2020). In this assay, upon binding of FGF14 to the Nav1.6 C-terminal tail, there is reconstitution of the NLuc and CLuc halves of the luciferase enzyme, which produces luminescence in the presence of substrate D-luciferin (Figures 2A,D).…”
Section: In-cell Testing Of Plev and Eyyv Using The Split Luciferase Complementation Assaymentioning
confidence: 99%
“…To evaluate the hypothesis that PLEV and/or EYYV could modulate FGF14:Nav1.6 complex assembly, an in-cell assay was used with a HEK293 cell line (hereafter coded as "Clone V" cells) stably expressing both CLuc-FGF14 and CD4-Nav1.6-NLuc (Shavkunov et al, 2012;Shavkunov et al, 2013;Shavkunov et al, 2015;Ali et al, 2016Ali et al, , 2018Wadsworth et al, 2019Wadsworth et al, , 2020Dvorak et al, 2020Dvorak et al, , 2021Singh et al, 2020;Wang et al, 2020). In this assay, upon binding of FGF14 to the Nav1.6 C-terminal tail, there is reconstitution of the NLuc and CLuc halves of the luciferase enzyme, which produces luminescence in the presence of substrate D-luciferin (Figures 2A,D).…”
Section: In-cell Testing Of Plev and Eyyv Using The Split Luciferase Complementation Assaymentioning
confidence: 99%
“…HEK293 cells were cultured as previously described [26,[29][30][31], with different concentrations of G418 (Invitrogen, Carlsbad, CA, USA) added to the media to ensure stable Na v 1.2 and Na v 1.6 expression.…”
Section: Cell Culturementioning
confidence: 99%
“…Clampex 9.2 software (Molecular Devices) was used to set experimental parameters, and electrophysiological equipment was interfaced to this software using a Digidata 1200 analog-digital interface (Molecular Devices). Acquired data was then analyzed as previously described [27,28,30,31,33].…”
Section: Whole-cell Voltage-clamp Recordings In Heterologous Cellsmentioning
confidence: 99%
See 1 more Smart Citation
“…Similar assays have facilitated the discovery of biased ligands for the nociception opioid peptide (NOP) [62] and serotonin HT1A [63] receptors. Although ion channel/transporter interactions with function-modulating proteins are not as well characterized compared with GPCRs, there is great potential to apply similar assays to those systems, as in a recent example where a peptide disrupting the Na v 1.6/fibroblast growth factor interaction was discovered [64]. In addition, intramolecular fluorescence/bioluminescence resonance energy transfer (FRET/BRET) sensors have been developed to monitor MP conformational changes in response to drug binding/activation [65,66].…”
Section: Hts Approachesmentioning
confidence: 99%